ProMIS Neurosciences Inc. Common Shares (ON) (PMN)
PMN trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.
Profile
| Field | Value |
|---|---|
| Ticker | PMN on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | Canada |
| IPO year | Not reported by the screener |
| SEC CIK | 0001374339 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | Canada |
Financials
Foreign filer: no machine-readable annual figure in SEC data.
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-12 |
| Cash and burn | $44.1M cash; operating cash flow -$10.4M a quarter. | Report 2026-09-30 |
| Shares outstanding | 8,996,862 (2026-11-12); 53,811,110 a year earlier; 18,885,254 three years earlier. 1y figure adjusted for splits (1-for-25 overall); 3y figure adjusted for splits (1-for-25 overall). | Cover page 2026-11-12 |
| Reverse splits, 3 years | 1; latest 1-for-25 on 2025-11-28 | Source 2025-11-28 |
| Shelf and offerings, 12 months | 2 S-3/F-3 shelf filings; 0 424B5 takedowns | Latest 2026-03-25 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Baker Tilly US, LLP, Tewksbury, Massachusetts, United States | PCAOB Form AP 2026-04-21 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $257K, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | Not filed | -$8.2M | -$9.4M | $44.1M | No debt tags | Needs four quarters | 10-Q 2026-11-12 |
| Q2 2026 2026-06-30 | Not filed | -$11.7M | -$10.4M | $53.4M | No debt tags | Needs four quarters | 10-Q 2026-08-13 |
| Q1 2026 2026-03-31 | Not filed | -$8.2M | -$12.4M | $63.8M | No debt tags | Needs four quarters | 10-Q 2026-05-12 |
| Q4 2025 2025-12-31 | Not filed | -$10.7M | -$9.3M | $6.1M | No debt tags | Needs four quarters | 10-K 2026-03-25 |
| Q3 2025 2025-09-30 | Not filed | -$11.6M | -$10.1M | $15.4M | No debt tags | Needs four quarters | 10-Q 2026-11-12 |
| Q2 2025 2025-06-30 | Not filed | -$10.1M | -$3.9M | $4.5M | No debt tags | Needs four quarters | 10-Q 2026-08-13 |
| Q1 2025 2025-03-31 | Not filed | -$7.3M | -$4.9M | $8.4M | No debt tags | Needs four quarters | 10-Q 2026-05-12 |
| Q4 2024 2024-12-31 | Not filed | -$238K | -$8.7M | $13.3M | No debt tags | Needs four quarters | 10-K 2026-03-25 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | S-3 | 2026-03-25 |
| Latest annual report | 10-K | 2026-03-25 |
| Latest quarterly / interim | 10-Q | 2026-11-12 |
| Latest current report | 8-K | 2026-11-12 |
| Latest proxy | DEFA14A | 2026-04-09 |
Source: SEC EDGAR submissions feed, 377 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -20.9% |
| 1 month | -62.0% |
| 3 months | -77.8% |
| Year to date | -51.8% |
| 1 year | -66.3% |
| From 52-week high | -86.7% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| NXTC | NextCure Inc. | $6.68 | +4.38% | $30.6M |
| SCYX | SCYNEXIS Inc. | $2.91 | -9.35% | $29.0M |
| BCTX | BriaCell Therapeutics Corp. Common Shares | $3.30 | -2.65% | $28.8M |
| NSRX | Nasus Pharma Ltd. | $2.66 | -7.32% | $31.2M |
| NNVC | NanoViricides Inc. | $1.24 | +0.81% | $31.7M |
| AARD | Aardvark Therapeutics Inc. | $1.26 | -5.26% | $27.6M |
| RMTI | Rockwell Medical Inc. | $6.76 | -4.38% | $26.9M |
| MIRA | MIRA Pharmaceuticals Inc. | $0.6310 | -4.38% | $26.5M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier